BACKGROUND & OBJECTIVE: 5-Aminoisoquinolinone(5-AIQ),a poly(adenosine 5'-diphosphate ribose) polymerase (PARP) inhibitor, plays an important role in inflammation, but its role in tumors is unclear. This study was to investigate the biological role of 5-AIQ-induced PARP inhibition in colon carcinoma cell line HT-29. METHODS: The expression of poly(adenosine 5'-diphosphate ribose) (PAR) and co-expression of PAR with P-selectin and intercellular adhesion molecule-1 (ICAM-1) in 45 specimens of colorectal carcinoma and 10 specimens of adjacent normal colorectal mucosa were detected by SP immunohistochemistry and double immunofluorescence staining. After treatment of 5-AIQ, the adhesion of colon carcinoma cell line HT-29 to human umbilical vein endothelial cells (HUVEC) was detected by adhesion experimentû the expression of PAR, P-selectin, and ICAM-1 in HT-29 cells was detected by SP immunohistochemistry. RESULTS: The positive rate of PAR was significantly higher in colorectal carcinoma than in control colorectal mucosa (77.8% vs. 10.0%, P < 0.05), and higher in colorectal carcinomas with metastasis than in colorectal carcinomas without metastasis (86.7% vs. 60.0%). PAR expression was correlated to P-selectin and ICAM-1 expression. Cell adhesion rate was significantly lower in 100, 300, and 500 mumol/L 5-AIQ-treated HT-29 cells than in control cells (55.79%, 46.31%, and 39.77% vs. 100%, P < 0.05). The protein levels of PAR, P-selectin, and ICAM-1 were significantly lower in 5-AIQ-treated HT-29 cells than in control cells (1.41+/-0.12 vs. 2.61+/-0.10, 1.57+/-0.13 vs. 2.73+/-0.16, 1.23+/-0.13 vs. 2.30+/-0.12, P < 0.05). CONCLUSIONS: PARP activity is enhanced in colorectal carcinoma. PARP inhibitor 5-AIQ can inhibit the adhesion of HT-29 cells to HUVECs, and the expression of PAR, P-selectin, and ICAM-1 in HT-29 cells.
BACKGROUND & OBJECTIVE:5-Aminoisoquinolinone(5-AIQ),a poly(adenosine 5'-diphosphate ribose) polymerase (PARP) inhibitor, plays an important role in inflammation, but its role in tumors is unclear. This study was to investigate the biological role of 5-AIQ-induced PARP inhibition in colon carcinoma cell line HT-29. METHODS: The expression of poly(adenosine 5'-diphosphate ribose) (PAR) and co-expression of PAR with P-selectin and intercellular adhesion molecule-1 (ICAM-1) in 45 specimens of colorectal carcinoma and 10 specimens of adjacent normal colorectal mucosa were detected by SP immunohistochemistry and double immunofluorescence staining. After treatment of 5-AIQ, the adhesion of colon carcinoma cell line HT-29 to human umbilical vein endothelial cells (HUVEC) was detected by adhesion experimentû the expression of PAR, P-selectin, and ICAM-1 in HT-29 cells was detected by SP immunohistochemistry. RESULTS: The positive rate of PAR was significantly higher in colorectal carcinoma than in control colorectal mucosa (77.8% vs. 10.0%, P < 0.05), and higher in colorectal carcinomas with metastasis than in colorectal carcinomas without metastasis (86.7% vs. 60.0%). PAR expression was correlated to P-selectin and ICAM-1 expression. Cell adhesion rate was significantly lower in 100, 300, and 500 mumol/L 5-AIQ-treated HT-29 cells than in control cells (55.79%, 46.31%, and 39.77% vs. 100%, P < 0.05). The protein levels of PAR, P-selectin, and ICAM-1 were significantly lower in 5-AIQ-treated HT-29 cells than in control cells (1.41+/-0.12 vs. 2.61+/-0.10, 1.57+/-0.13 vs. 2.73+/-0.16, 1.23+/-0.13 vs. 2.30+/-0.12, P < 0.05). CONCLUSIONS:PARP activity is enhanced in colorectal carcinoma. PARP inhibitor 5-AIQ can inhibit the adhesion of HT-29 cells to HUVECs, and the expression of PAR, P-selectin, and ICAM-1 in HT-29 cells.